Print Email Facebook Twitter Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM Title Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM Author Brussaard, H.E. Gevers Leuven, J.A. Frölich, M. Kluft, C. Krans, H.M.J. Gaubius Instituut TNO Publication year 1997 Abstract Oestrogen replacement therapy is associated with a decreased risk of cardiovascular disease in postmenopausal women. Patients with non-insulin- dependent diabetes mellitus (NIDDM) have an increased cardiovascular risk. However, oestrogen replacement therapy is only reluctantly prescribed for patients with NIDDM. In a double blind randomized placebo controlled trial we assessed the effect of oral 17 β-estradiol during 6 weeks in 40 postmenopausal women with NIDDM. Glycated haemoglobin (HbA(1c)), insulin sensitivity, suppressibility of hepatic glucose production, lipoprotein profile and parameters of fibrinolysis were determined. The oestrogen treated group demonstrated a significant decrease of HbA(1c) and in the normotriglyceridaemic group a significantly increased suppression of hepatic glucose production by insulin. Whole body glucose uptake and concentrations of non-esterified fatty acids did not change. LDL-cholesterol- and apolipoprotein B levels decreased, and HDL-cholesterol, its subfraction HDL2-cholesterol and apolipotrotein A1 increased. The plasma triglyceride level remained similar in both groups. Both the concentration of plasminogen activator inhibitor-1 antigen and its active subfraction decreased. Tissue type plasminogen activator activity increased significantly only in the normotriglyceridaemic group. Oestrogen replacement therapy improves insulin sensitivity in liver, glycaemic control, lipoprotein profile and fibrinolysis in postmenopausal women with NIDDM. For a definite answer as to whether oestrogens can be more liberally used in NIDDM patients, long term studies including the effect of progestogens are necessary. Subject BiologyCoagulation factorsGlucose regulationHepatic glucose productionInsulin sensitivityLipoprotein profilesNon-insulin-dependent diabetes mellitusOestrogen therapyApolipoprotein a1Apolipoprotein bBlood clotting factorGlycosylated hemoglobinHigh density lipoprotein cholesterolInsulinLow density lipoprotein cholesterolPlasminogen activatorAdultAgedCardiovascular diseaseCardiovascular riskClinical articleEstrogen therapyGlucogenesisNon insulin dependent diabetes mellitusPostmenopauseC-PeptideCholesterolDiabetes Mellitus, Type 2Double-Blind MethodEstradiolEstrogen Replacement TherapyFatty Acids, NonesterifiedFemaleFibrinolysisHemoglobin A, GlycosylatedHumansInsulin ResistanceLipidsLipoproteinsMiddle AgedPlasminogen Activator Inhibitor 1PostmenopauseTissue Plasminogen ActivatorTriglycerides To reference this document use: http://resolver.tudelft.nl/uuid:6a0a6d23-0b1f-41e5-9512-efe4d2bc1211 DOI https://doi.org/10.1007/s001250050758 TNO identifier 233999 ISSN 0012-186X Source Diabetologia, 40 (7), 843-849 Document type article Files To receive the publication files, please send an e-mail request to TNO Library.